Storage Condition
Refer MSDS for complete information
Application Notes
Useful research chemical for a range of applications
Hazard Compound
Refer MSDS for complete information
Baricitinib-D4 (azetidine-2,2-d2)(Ethyl-1,1-d2) is a drug product that is used as an analytical standard for HPLC, as well as in research and development of drugs.
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
Baricitinib-D4 (azetidine-2,2-d2)(Ethyl-1,1-d2) usage and description
Baricitinib-D4 (azetidine-2,2-d2)(Ethyl-1,1-d2) is a deuterated form of Baricitinib, a selective and reversible inhibitor of Janus kinase (JAK) 1 and 2. It is used for the treatment of moderate to severe rheumatoid arthritis in adult patients who have not responded to other treatments. Baricitinib-D4 works by blocking the activity of JAK1 and JAK2, which are signaling molecules that play a crucial role in the immune system. By blocking these molecules, Baricitinib-D4 helps to reduce inflammation and pain in the joints, improving the overall quality of life of patients with rheumatoid arthritis.
Chemically, Baricitinib-D4 has the molecular formula C16H14D4N7O and a molecular weight of 330.4 g/mol. It is a white to off-white crystalline powder that is soluble in dimethyl sulfoxide, slightly soluble in water, and practically insoluble in ethanol. Baricitinib-D4 is administered orally, with a recommended dose of 4 mg once daily.
Baricitinib-D4 has been extensively studied in clinical trials, and its safety and efficacy have been demonstrated in numerous studies. However, it should be used with caution in patients with a history of tuberculosis, liver or kidney problems, and those who are taking other medications that affect the immune system. Overall, Baricitinib-D4 is a promising treatment option for patients with rheumatoid arthritis who have not responded to other therapies.